Occult B infection in haematology and blood transfusion;Ukryte zakażenie wirusem HBV w hematologii i transfuzjologii

Acta Haematologica Polonica

Volumn 40, Issue 2, 2009, Pages 435-449

  Brojer, Ewa ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

Author keywords

Anti HBc; HBsAg; HBV DNA; Immunosuppression; Occult B infection; Reactivation

Indexed keywords

ALANINE AMINOTRANSFERASE; ALEMTUZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOTRANSPLANTATION; ANTIVIRAL THERAPY; B CELL LYMPHOMA; BLOOD TRANSFUSION; CAUSE OF DEATH; CD8+ T LYMPHOCYTE; DIAGNOSTIC TEST; DNA VIRUS; DRUG DOSE REGIMEN; EUROPE; GENE MUTATION; HEMATOLOGIC DISEASE; HEMATOLOGY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LIVER FAILURE; OCCULT BLOOD; POLAND; REVIEW; RISK FACTOR; SEROCONVERSION; SEROLOGY; SYMPTOMATOLOGY; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 69249140638     PISSN: 00015814     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Juszczyk J: Wirusowe zapalenia wa̧troby. PZWL, Warszawa, 1999
2. www.who.int
3. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000;33:992-997
4. Brechot Ch, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent Hepatitis B Virus Infection in Subjects Without Hepatitis B Surface Antigen: C linically Siggnificant or Purely "Occult"?. Hepatology 2001;34;194-201.
5. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994;93:230-239 (Pubitemid 24030841)
6. Czarkowski MP, Rosińska M, Hepatitis B in Poland in 2005. Przegl Epidemiol 2007;61:273-279
7. Kuśmierczyk J, Zatorska J, Raś J i wsp. Prevalence of anti-HBc anibodies in blood donors in the South region of Poland. Vox Sang 2006, 9: suppl 3: 56.
8. Raimondo G, Allain JP, Brunetto MR i wsp. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-757
9. Brojer E, Grabarczyk P, Liszewski G i wsp. Characterization of HBV DNA+/HBsAg- blood donors in Poland identified by triplex NAT. Hepatology. 2006;44:1666-1674
10. Candotti D, Grabarczyk P, Ghiazza P i wsp. Characterization of occult hepatitis B virus from blood donors carrying genotype A2 or genotype D strains. Journal of Hepatology 2008; 49; 537-547.
11. Manzini P, Abate ML, Valpreda C i wsp Evidence of acute primary occult hepatitis B virus infection in an Italian repeat blood donor. Transfusion. 2009 Jan 2
12. Gerlich WH. Diagnostic problems caused by HBsAg mutant-a consensus report of an expert meeting. Intervirology 2004; 47:310-313
13. Alexopoulou A, Theodorou M, Dourakis S.P. i wsp. Hepatitis B Virus Reactivation in Patients Receiving Chemotherapy for Malignancies: Role of Precore Stop-codon and Basic Core Promoter Mutations. J Viral Hepat. 2006;13; 591-596. (Pubitemid 44232542)
14. Dai MS, Lu JJ, Chen YC, Perng CL, Chao TY. Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients. Cancer 2001; 92: 2927-2932. (Pubitemid 33091930)
15. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment af viral hepatitis B reactivation in patients with haematological malignancies. 2007; 136; 699-712.
16. Liang R. How I treat and Monitor Viral Hepatitis B Infection in Patients Receiving Intensive Immunosuppressive Therapies or Undergoing Hematopoietic Stem Cell Transplantation. Blood First Edition Paper online January 14 2009;
17. Kleinman SH, Kuhns MC, Todd DS i wsp. Frequency of HBV-DNA detection in US blood donors testing positive for the presence of anti-HBC: implications for transfusion transmission and donor screening. Transfusion 2003;43:696-704.
18. Firpi R.J., Nelson D.R. Management of viral hepatitis in hematologic malignancies. Blood Reviews 2008; 22; 117-126.
19. Chen MH, Hsiao LT, Chipu TJ i wsp. High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin,s lymphoma.Ann Hematol 2008; 87; 475-480.
20. Yeo W, Chan T.C, Leung N.W.Y. i wsp. Hepatitis B Virus Reactivation in Lymphoma Patients With Prior Resolved Hepatitis B Undergoing Anticancer Therapy With or Without Rituximab. American Society of Clinical Oncology 2009; 4; 605-611.
21. Wu , Huang YH, Lee PC I wsp. Fatal Reactivation of Hepatitis B Virus in a Patient Who Was Hepatitis B Surface Antigen Negative and Core Antibody Positive Before Receiving Chemotherapy for Non-Hodgkin Lymphoma. J Clin Gastroenterol 2009,
22. Sarrecchia C, Cappelli A, Aiello P HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005; 11:189-191 (Pubitemid 41216450)
23. Onozawa M, Hashino S, Izumiyama K i wsp. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79: 616-619.
24. Persico, E, De Renzo, A, La Mura i wsp. Occult hepatitis B virus infection in patients with non-Hodgkin lymphoma: the need for early diagnosis in anti-Hbc positive patients. Gut 2007; 56: 1470-2147
25. Picardi M, Pane F, Quintarelli C I wsp. Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations. Haematologica 2003; 88: 1296-1303.
26. Toyoda H, Hayashi K, Murakami Y i wsp. Prevalence and clinical implications of occult hepatitis B viral infection in hemophilia patients in Japan Journal of Medical Virology Volume73, 2, 195-199
27. Windyga J, Brojer E, Gronowska A i wsp: Preliminary results of HBV DNA testing of Polish haemophilia patients - lack of occult HBV infection. Haemophilia 2006,12,380-383.
28. Comjeevaram HS, Lok AS; Occult Hepatitis B virus infections hidden menace. Hepatology, 2001; 34: 204-205
29. Hui CK, Sun J, Au WY i wsp.: Occult hepatitis B virus infection in haematopoetic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42: 813-819 (Pubitemid 40693197)
30. Allain JP. Occult hepatitis B infection: implications in transfusion. Vox Sang 2004; 86: 83-91 (Pubitemid 38436885)
31. Brojer E, Dobrowolna M, Górska P, i wsp.: Analiza wyników procedury czuwania nad bezpieczeństwem krwi w odniesieniu do dawców z ukrytym zakażeniem HBV. Acta Haemat Pol. 2007; 064; 103-104
32. Levicnik-Stezinar S, Rahne-Potokar U, Candotti D, Lelie N, Allain JP Anti-HBs positive occult hepatitis B virus carrier blood infectious in two transfusion recipients. J Hepatol. 2008; 48: 1022-1025
33. Grabarczyk P, Liszewski G, Mikulska M, Kopacz A, Łȩtowska M, Brojer E. Praktyczne konsekwencje wprowadzenia badań DNA HBV u dawców krwi. Acta Haematol Pol 2009; 40: 45-54.
34. Reesink HW, Engelfriet CP, Henn G i wsp. Occult hepatitis B infection in blood donors. Vox Sang. 2008;94:153-166
35. Umemura T, Tanaka E, Kijyosawa K i wsp. Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in Japan.Clinical Infectious Diseases 2008; 47; e52-56.
36. Lau GK, Leung YH, Fong DY, i wsp. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002; 99:2324-2330
37. Hui CK, Cheung WW, Zhang HY i wsp: Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 131: 59-68
38. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004; 83: 270-275.
39. Rossi G, Pelizzari A, Motta M, Puoti M. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58-62. (Pubitemid 32995093)